Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 12 results:
Συντάκτης Τίτλος [ Τύπος] Έτος Φίλτρα: Συντάκτης is Kalofonos, Haralabos P [Clear All Filters]
Bevacizumab in the treatment of breast cancer..
Cancer Treat Rev. 36(1), 75-82.
(2010). Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study..
Oncol Rep. 27(1), 216-24.
(2012). Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial..
Breast Cancer Res Treat. 116(1), 131-43.
(2009). Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer..
Anticancer Res. 30(10), 4325-33.
(2010). KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study..
BMJ Open. 4(5), e004652.
(2014). Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group..
Clin Breast Cancer. 10(3), 230-7.
(2010). PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients..
Cancer Chemother Pharmacol. 75(6), 1289-301.
(2015). Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial..
Breast Cancer Res Treat. 132(2), 609-19.
(2012).
(2010).
(2011). Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation..
Oncology. 76(4), 275-85.
(2009). The upgraded role of HER3 and HER4 receptors in breast cancer..
Crit Rev Oncol Hematol. 74(2), 73-8.
(2010).